UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Oct

    29

    UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

    Read More Share:linkedin| twitter| email| facebook

    Oct

    27

    Generalized myasthenia gravis management with shared decision-making

    Read More Share:linkedin| twitter| email| facebook

    May

    30

    Recognizing Myasthenia Gravis Month – The Importance of Addressing Unmet Patient Needs

    At UCB, we work 365-days-a-year to find new ways to deliver solutions, peace of mind, and opportunities to people living with severe diseases because everyone deserves to live the best life they can.

    Read More Share:linkedin| twitter| email| facebook

    Oct

    15

    Powering the dreams of people impacted by myasthenia gravis (MG)

    Read More Share:linkedin| twitter| email| facebook

    Oct

    11

    UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

    Read More Share:linkedin| twitter| email| facebook

    Apr

    12

    UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

    Read More Share:linkedin| twitter| email| facebook

    Jan

    03

    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

    Read More Share:linkedin| twitter| email| facebook

    Nov

    01

    UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

    Read More Share:linkedin| twitter| email| facebook

    Jul

    21

    UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

    Read More Share:linkedin| twitter| email| facebook

    Jun

    27

    Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2025 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: August 2025